(Q45154773)

English

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

scientific article published in December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Johannes Bükki

object named as

J Bükki

6

0 references

object named as

C Pozzo

1

0 references

author name string

C Barone

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

J Szanto

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

E Padi

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

C Peschel

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

V Gorbunova

7

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

V Valvere

8

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

J Zaluski

9

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

M Biakhov

10

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

E Zuber

11

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

C Jacques

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

R Bugat

13

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1773-1781

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Chemotherapy options for gastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH473

21 January 2018

Identifiers

10.1093/ANNONC/MDH473

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45154773&oldid=2068147243"